文献速递血栓与止血

抗PF4/H抗体与抗PF4抗体协同作用增加HIT中的细胞活化及血栓风险

Cooperative effect between anti-PF4/H and anti-PF4 antibodies increases cell activation and thrombotic risk in HIT.
PubMed 文献 · Blood Adv · 2025-01-01

研究使用嵌合单克隆IgG1抗体5B9(抗PF4/H)和1E12(抗PF4),发现非活化浓度1E12与5B9共孵育可显著活化血小板,该协同作用依赖Fc及FcγRIIA;在流动条件下诱导血栓形成,在人FcγRIIA/人PF4转基因小鼠中两抗体共同注射总是引起血小板减少,三分之一小鼠出现肺血栓。

要点

  • 非活化浓度1E12与5B9共孵育可显著活化血小板,作用依赖Fc及FcγRIIA。
  • 5B9在非活化浓度1E12存在下,无肝素时流动条件下诱导血栓形成。
  • 两抗体共同注射转基因小鼠总是发生血小板减少,三分之一出现肺血栓。

核心结论

  • 不同特异性的抗PF4抗体之间可能存在功能协同,促进细胞活化、血小板减少和血栓形成。
  • 该过程可能增加HIT患者即使停用肝素后的血栓风险。

研究设计与样本

  • 使用嵌合单克隆IgG1抗体5B9(特异性针对PF4/H复合物)和1E12(特异性针对PF4单独)进行体外实验。
  • 在洗涤血小板、流动条件下及人FcγRIIA/人PF4转基因小鼠中评估细胞活化、血小板计数和血栓形成。

主要发现

  • 5B9与洗涤血小板无肝素共孵育不诱导血小板活化,但非活化浓度1E12存在时观察到显著血小板活化。
  • 该功能协同依赖Fc,涉及FcγRIIA受体,用1E12或5B9的F(ab')2片段或ibrutinib处理后不再检测到。
  • 5B9在非活化浓度1E12存在下,无肝素时流动条件下诱导血栓形成。
  • 两抗体共同注射人FcγRIIA/人PF4转基因小鼠,总是发生血小板减少,三分之一注射小鼠出现肺血栓,与注射5B9和肝素后观察到的相似。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy, frequently associated with thrombosis. Immunoglobulin G (IgG) antibodies to heparin-platelet factor 4 (PF4/H) complexes play a central role in HIT by activating platelets and leukocytes via Fc gamma Receptor IIa (FcγRIIA). However, some patients also develop IgG against unmodified PF4 (anti-PF4), but their implication in the pathophysiology of HIT is unclear. Therefore, we assessed the impact of the joint presence of anti-PF4/H and anti-PF4 antibodies on cellular activation, platelet count, and thrombus formation, using chimeric monoclonal IgG1 antibodies specific for either PF4/H complexes (5B9) or PF4 alone (1E12). As expected, 5B9 coincubated with washed platelets without heparin did not induce platelet activation, but when a nonactivating concentration of 1E12 was present with 5B9, significant platelet activation was observed. This functional cooperation was Fc dependent and involved FcγRIIA receptors, given that it was no longer detectable with F(ab')2 fragments of 1E12 or 5B9 or with ibrutinib, which inhibits the FcγRIIA pathway. 5B9 at a nonactivating concentration of 1E12 also induced thrombus formation without heparin under flow conditions. Furthermore, when the 2 antibodies were injected together into human FcγRIIA/human PF4 transgenic mice, thrombocytopenia always occurred, with pulmonary thrombi in one-third of the injected mice, similar to that observed after injection of 5B9 and heparin. These results support that functional cooperation may exist between anti-PF4 antibodies of different specificity and promote cell activation, thrombocytopenia, and thrombosis. This process may also increase the risk of thrombosis in HIT even after heparin treatment has been discontinued.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Billy S, Vayne C, Bertin O, et al. Cooperative effect between anti-PF4/H and anti-PF4 antibodies increases cell activation and thrombotic risk in HIT. Blood Adv. 2025. PMID: 40101232. doi:10.1182/bloodadvances.2024015095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。